Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

727
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
727

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Presentation and Outcomes of Sporadic Neuroendocrine Neoplasms in Young Adults.

European journal of endocrinology·2026
Same author

Thyroid hormone therapy in a population cohort over two decades indicates persistent overtreatment.

European thyroid journal·2026
Same author

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial.

ESMO open·2025
Same author

Entropy Spectroscopy of a Bilayer Graphene Quantum Dot.

Physical review letters·2025
Same author

Thyroid Hormone Treatment for Hypercholesterolemia in Euthyroid Patients: Results From a European Survey of Thyroid Specialists.

Clinical endocrinology·2025
Same author

Acceptance, Drivers, and Barriers to Use of mHealth Apps to Improve Quality of Life in Female Patients Affected by Hypothyroidism: Cross-Sectional Study.

JMIR formative research·2025

Related Experiment Video

Updated: Mar 22, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K

Sunitinib Efficacy in Patients with Advanced pNET in Clinical Practice.

H Lahner1, A Rinke2, N Unger1

  • 1Department of Endocrinology and Metabolism, Division of Laboratory Research, University of Duisburg-Essen, Essen, Germany.

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|April 22, 2016
PubMed
Summary
This summary is machine-generated.

Sunitinib therapy offers improved progression-free survival for advanced pancreatic neuroendocrine tumors (pNETs). Real-world data show similar effectiveness and tolerability to clinical trials, supporting its use in practice.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.1K
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

12.4K

Related Experiment Videos

Last Updated: Mar 22, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.6K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.1K
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

12.4K

Area of Science:

  • Oncology
  • Clinical Pharmacology

Background:

  • Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms.
  • Sunitinib is approved for advanced pNETs, but real-world data on its effectiveness and safety are limited.

Purpose of the Study:

  • To evaluate the effectiveness, safety, and tolerability of sunitinib in a real-world cohort of patients with advanced pNETs.
  • To compare clinical practice outcomes with phase III trial results.

Main Methods:

  • Retrospective analysis of 21 patients with advanced, differentiated pNETs treated with sunitinib.
  • Assessment of treatment effectiveness using RECIST criteria and progression-free survival (PFS).

Main Results:

  • Objective response (partial response or stable disease) observed in 57% of patients (12/19).
  • Median PFS was 7.0 months; 6-month event-free probability was 52.6%.
  • No significant correlation found between Ki-67 index, age, or disease duration and sunitinib response.

Conclusions:

  • Sunitinib demonstrates comparable effectiveness and tolerability in clinical practice to phase III trial findings for advanced pNETs.
  • Real-world data support sunitinib as a valuable treatment option for advanced pNETs.